Editas Medicine is a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Their goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer. 

Biotechnology

Editas Medicine

Gilmore O’Neill

Gregory Whitehead

Erick J. Lucera

Greg Whitehead

Baisong Mei

Caren Deardorf

Linda C. Burkly

Linea Aspesi

Charlene Stern

Leadership Team

Clinical Development and Trials

��

Teams at Editas Medicine

Leadership Team

Clinical Development and Trials

��������

Teams at Editas Medicine

Leadership Team

Clinical Development and Trials

��